Research Analysts Offer Predictions for TRDA Q2 Earnings
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) – Research analysts at Roth Capital lowered their Q2 2025 earnings estimates for shares of Entrada Therapeutics in a report released on Sunday, May 11th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.89) for the quarter, down from their […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) – Research analysts at Roth Capital lowered their Q2 2025 earnings estimates for shares of Entrada Therapeutics in a report released on Sunday, May 11th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.89) for the quarter, down from their […]
